A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Latest Information Update: 12 Nov 2019
Price :
$35 *
At a glance
- Drugs Ubidecarenone (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Berg Pharma
- 28 Sep 2019 According to a Berg Pharma media release, Dr. Vivek Subbiah is the primary investigator for this trial.
- 28 Sep 2019 Results presented in the Berg Pharma media release.
- 28 Sep 2019 According to a Berg Pharma media release, data from this trial were presented during a poster session at the European Society for Medical Oncology (ESMO) annual meeting in Barcelona.